DTIL

Precision Biosciences, Inc. develops gene editing therapies using its proprietary ARCUS technology, which employs sequence-specific DNA-cutting enzymes to modify the DNA of living cells. The company focuses on creating treatments for hard-to-treat conditions, including rare genetic diseases and chronic infections such as hepatitis B and Duchenne muscular dystrophy. Precision Biosciences operates primarily in the biotechnology sector, targeting healthcare providers and patients in the United States and internationally.